Determinants of prescription drug use by adolescents with intellectual disabilities in Taiwan

Research in Developmental Disabilities

Volumn 30, Issue 6, 2009, Pages 1354-1366

  Yen, Chia Feng ^a   Lin, Jin Ding ^b   Loh, Ching Hui ^c   Shi, Leiyu ^d   Hsu, Shang Wei ^e  

^a NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^b FU JEN CATHOLIC UNIVERSITY   (Taiwan)

^c TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^e ASIA UNIVERSITY   (Taiwan)

Author keywords

Adolescents with intellectual disabilities; Healthy behavior; Medical care; Prescribed medication; Preventive health care

Indexed keywords

HEPATITIS B VACCINE; INFLUENZA VACCINE; PNEUMOCOCCUS VACCINE;

ADOLESCENT; AGE DISTRIBUTION; ARTICLE; CAREGIVER; CHILD; CIGARETTE SMOKING; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DOWN SYNDROME; EPILEPSY; FEMALE; GASTROINTESTINAL SYMPTOM; HEALTH BEHAVIOR; HEALTH CARE UTILIZATION; HEALTH STATUS; HEALTH SURVEY; HUMAN; INTELLECTUAL IMPAIRMENT; MAJOR CLINICAL STUDY; MALE; MEDICAL CARE; MENTAL DISEASE; MORBIDITY; OUTPATIENT CARE; POPULATION RESEARCH; PRESCRIPTION; PREVALENCE; PREVENTIVE HEALTH SERVICE; RISK ASSESSMENT; SCHOOL CHILD; TAIWAN;

ADOLESCENT; CHILD; DATA COLLECTION; HEALTH SERVICES NEEDS AND DEMAND; HUMANS; MENTALLY DISABLED PERSONS; PRESCRIPTION DRUGS; TAIWAN;

EID: 69249209709     PISSN: 08914222     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ridd.2009.06.002     Document Type: Article

References (60)

1. Aman M.G., and Singh N.N. Pharmacological intervention. In: Matson J.L., and Mulick J.L. (Eds). Handbook of mental retardation (1983), Oxford University Press, Oxford, Pergamon
2. Aman M.G., Singh N.N., and White A.J. Caregiver perceptions of psychotropic medication in residential facilities. Research in Developmental Disabilities 8 (1987) 449-465
3. Andre F.E., Booy R., Bock H.L., Clemens J., Datta S.K., John T.J., Lee B.W., Lolekha S., Peltola H., Ruff T.A., Santosham M., and Schmitt H.J. Vaccination greatly reduce disease, disability, death and inequity worldwide. Bulletin of World Health Organization 86 (2008) 140-146
4. Arscott K., Kroese B.S., and Dagnan D. A study of the knowledge that people with intellectual disabilities have of their prescribed medication. Journal of Applied Research in Intellectual Disabilities 13 (2000) 90-99
5. Beange H. Medical disorders in adults with mental retardation: A population study. American Journal of Mental Retardation 99 (1995) 595-604
6. Beange H. Caring for a vulnerable population. Medical Journal of Australia 164 (1996) 159-160
7. Beange H., Lennox N., and Parmenter T.R. Health targets for people with an intellectual disability. Journal of Intellectual Disability Research 24 (1999) 283-297
8. Briggs R. Monitoring and evaluating psychotropic drug use for persons with mental retardation: A follow-up report. American Journal on Mental Retardation 6 (1989) 633-639
9. Brylewski J., and Duggan L. Antipsychotic medication for challenging behaviour in people with intellectual disability: A systematic review of randomized controlled trials. Journal of Intellectual Disability Research 43 (1999) 360-371
10. Christian L., Snycerski S.M., Singh N.N., and Poling A. Direct service staff and their perceptions of psychotropic medication in non-institutional settings for people with intellectual disability. Journal of Intellectual Disability Research 43 (1999) 88-93
11. Christianson A.L., Zwane M.E., Manga P., Rosen E., Venter A., Downs D., and Kromberg J.G.R. Children with intellectual disability in rural South Africa: Prevalence and associated disability. Journal of Intellectual Disability Research 46 (2002) 179-186
12. Clarke D.J., Kelley S., Thinn K., and Corbett J.A. Psychotropic drugs and mental retardation. Journal of Mental Deficiency Research 34 (1990) 385-395
13. Deb S. Epidemiology and treatment of epilepsy in patients who are mentally retarded. CNS Drugs 13 (2000) 117-128
14. Delong G.R. Intellectual disability: Understanding its development, causes, classification, evaluation, and treatment. New England Journal of Medicine 354 (2006) 1540-1541
15. Einfeld S.L., Piccinin A.M., Mackinnon A., Hofer S.M., Taffe J., Gray K.M., Bontempo D.E., Hoffman L.R., Parmenter T., and Tonge B.J. Psychopathology in young people with intellectual disability. The Journal of the American Medical Association 25 (2006) 2981-2989
16. Evenhuis H.M., Henderson C.M., Beange H., Lennox N., and Chicoine B. Healthy ageing-adults with intellectual disabilities: Physical health issues. Journal of Applied Research in Intellectual Disabilities 14 (2001) 175-194
17. Field L.T., Murphy R.J., Reagan M.W., and Peterson J.L. An assessment programme to reduce drug use with the mentally retarded. Hospital and Community Psychiatry 31 (1980) 771-773
18. Findholt N., and Emmett C. Impact of interdisciplinary review on psychotropic drug use with persons who have mental retardation. Mental Retardation 28 (1990) 41-46
19. Galli-Carminati G., Chauvet I., and Deriaz N. Prevalence of gastrointestinal disorders in adult clients with pervasive developmental disorders. Journal of Intellectual Disability Research 50 (2006) 711-718
20. Grosheide P., and Van Damme P. Prevention and control of hepatitis B in the community. Communicable disease series, No. 1 (1996), Viral Hepatitis Prevention Board, Wilrijk, Belgium
21. Harper D.C., and Wadsworth J.S. Behavioral problems and medication utilization. Mental Retardation 31 (1993) 97-103
22. Hung Y.T. Sampling. Survey Research (2001), National Cheng-Chi University, Taipei, Taiwan pp. 75-125
23. Hung Y.T. Comparisons of population, sampling and coverage in surveys Taiwan. Survey Research 15 (2005) 9-44
24. Inoue F. A clinical pharmacy service to reduce psychotropic medication use in an institution for mentally handicapped persons. Mental Retardation 20 (1982) 70-74
25. Jacobson J. Problem behaviour and psychiatric impairment with a developmentally disabled population III: Psychotropic medication. Research in Developmental Disabilities 9 (1988) 23-38
26. James D. Monitoring drugs in hospitals for the mentally handicapped. British Journal of Psychiatry 142 (1983) 163-165
27. Kiernan C., Reeves D., and Alborz A. The use of anti-psychotic drugs with adults with intellectual disabilities and challenging behaviour. Journal of Intellectual Disability Research 39 (1995) 263-274
28. Leeder S.R., and Dominello A. Health, equity and intellectual disability. Journal of Applied Research in Intellectual Disabilities 18 (2005) 97-100
29. Lim W.W.C. Use of psychoactive medication in Hong Kong institutions for adults with severe to profound learning disabilities: A retrospective study and economic analysis. Journal of Applied Research in Intellectual Disabilities 20 (2007) 529-538
30. Lin, J. D, Wu, J. L., Li, C. W., & Yen, C. F. (2001). The health policy development for persons with intellectual disability in Taiwan. The research report of Department of Health, Taiwan: pp. 1-132 (DOH90-TD-1153).
31. Lin J.D., Li C.W., Yen C.F., Wu J.L., Chow M.J., Loh C.W., and Lai C.Y. Epilepsy and healthcare utilization among people with intellectual disability: A national survey. Journal of Disability Research (Taiwan) 1 (2003) 65-73
32. Lin J.D., Loh C.H., Yen C.F., Li C.W., Chwo M.J., and Wu J.L. Medical care services for people with intellectual disabilities living in the general community: A cross-sectional survey of inpatient care utilization in Taiwan 2001. Disability & Rehabilitation 29 (2007) 1411-1416
33. Lin J.D., Wu J.L., and Lee P.N. Utilization of inpatient care and its determinants among persons with intellectual disabilities in day care institutions in Taiwan. Journal of Intellectual Disability Research 48 (2004) 655-662
34. Lin J.D., Yen C.F., Loh C.H., Hsu S.W., Haung H.C., Tang C.C., Li C.W., and Wu J.L. A cross-sectional study on the characteristics and determinants of emergency care utilization among people with intellectual disabilities in Taiwan. Research in Developmental Disabilities 27 (2006) 657-667
35. Linaker O.M. Frequency and determinants for psychotropic drug use in an institution for the mentally retarded. British Journal of Psychiatry 156 (1990) 525-530
36. Lott I.T., McGregor M., Engelman L., Touchette P., Tournay A., Sandman C., Fernandez G., Plon L., and Walsh D. Longitudinal prescribing patterns for psychoactive medications in community-based individuals with developmental disabilities: Utilization of pharmacy records. Journal of Intellectual Disability Research 48 (2004) 563-571
37. Mason J., and Scior K. 'Diagnostic overshadowing' amongst clinicians working with people with intellectual disabilities in the UK. Journal of Applied Research in Intellectual Disabilities 17 (2004) 85-90
38. Matson J.L., González M.L., Smith K.R., Terlonge C., Thorson R.T., and Dixon D.R. Assessing side effects of pharmacotherapy treatment of bipolar disorder: A 20-year review of the literature. Research in Developmental Disabilities 27 (2006) 467-500
39. McGrother C.W., Hauck A., Bhaumik S., Thorp C., and Tomb N. Community care for adults with learning disability and their carers: Needs and outcomes from the Leicestershire register. Journal of Intellectual Disability Research 40 (1996) 183-190
40. In: Millman M. (Ed). Access to health care in American/Committee on Monitoring Access to Personal Health Care Services (1993), National Academy Press, Washington, DC
41. Physically and Mentally Disabled Citizens Protection Act. (2004). President Order Hua-Tsung-Yi-Yi-Tzu No. 09300117621 on June 23, 2004. http://sowf.moi.gov.tw/english/071/Physically%20and%20Mentally%20Disabled%20Citizens%20Protection%20Act.htm.
42. Poindexter A.R. Psychotropic drug patterns in a large ICF/MR facility: A ten-year experience. American Journal on Mental Retardation 93 (1989) 624-626
43. Price Evans A.D. Genetic factors in drug therapy: Clinical and molecular pharmacogenetics (1993), Cambridge University Press, Cambridge, England
44. Quellettee-Kuntz H. Understanding health disparities and inequities faced by individuals with intellectual disabilities. Journal of Applied Research in Intellectual Disabilities 18 (2005) 113-121
45. Rimmer J.H. Health promotion for people with disabilities: The emerging paradigm shift from disability prevention to prevention of secondary conditions. Physical Therapy 79 (1999) 495-502
46. Rimmer J.H., and Braddock D. Health promotion for people with physical, cognitive and sensory disabilities: An emerging national priority. American Journal of Health Promotion 16 (2002) 220-224
47. Rimmer J.H., Braddock D., and Marks B. Health characteristics and behaviours of adults with mental retardation residing in three living arrangements. Research in Developmental Disabilities 16 (1995) 489-499
48. Rimmer J.H., Braddock D., and Pitetti K.H. Research on physical activity and disability: An emerging national priority. Medicine and Science in Sports and Exercise 28 (1996) 1366-1372
49. Rurangirwa J., Van Naarden Braun K., Schendel D., and Yeargin-Allsopp M. Healthy behaviors and lifestyles in young adults with a history of developmental disabilities. Research in Developmental Disabilities 27 (2006) 381-399
50. Santosh P.J., and Baird G. Psychopharmacotherapy in children and adults with intellectual disability. The Lancet 354 (1999) 231-240
51. Singh N.N., Ellis C.R., Donatelli L.S., Williams D.E., Ricketts R.W., Goza A.B., Perlman N., Everly D.E., Best A.M., and Singh Y.N. Professionals' perceptions of psychotropic medication in residential facilities for individuals with mental retardation. Journal of Intellectual Disability Research 40 (1996) 1-7
52. Sullivan S.G., Slack-Smith L.M., and Hussain R. Understanding the use of breast cancer screening services by women with intellectual disability. Sozial- und Präventivmedizin 49 (2004) 398-405
53. Taylor N.S., Standen P.J., Cutajar P., Fox D., and Wilson D.N. Smoking prevalence and knowledge of associated risks in adult attenders at day centres for people with learning disabilities. Journal of Intellectual Disability Research 48 (2004) 239-144
54. UK Department of Health. Valuing people: A new strategy for learning disability for the 21st century (2001), Department of Health, London
55. van Schrojenstein Lantman-de Valk H.M.J., Metsemakers J.F.M., Haveman M.J., and Crebolder H.F.J.M. Health problems in people with intellectual disability in general practice. Family Practice 17 (2000) 405-407
56. Vellinga A., Van Damme P., and Meheus A. Hepatitis B and C in institutions for individuals with intellectual disability. Journal of Intellectual Disability Research 43 (1999) 445-453
57. Weber W.W. Pharmacogenetics (1997), Oxford University Press, New York
58. White A. Changing patterns of psychoactive drug use with the mentally retarded. New Zealand Medical Journal 96 (1983) 686-688
59. Wilkinson G.R. Drug metabolism and variability among patients in drug response. The New England Journal of Medicine 352 (2005) 2211-2221
60. Wilkinson J.E., Culpepper L., and Cerreto M. Screening tests for adults with intellectual disabilities. Journal of American Board on Family Practice 20 (2007) 399-407